<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Stochastic optimisation model parameters across solution stages</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th align="left">
     <bold>Stage 1– How many vaccine candidates would ideally need to enter into preclinical, or phase 1, or phase 2, to achieve at least one phase 2a outcome by EID?</bold>
    </th>
    <th align="left">
     <bold>Stage 2</bold>
     <xref rid="tbl2fn1" ref-type="table-fn">*</xref>
     <bold>– How much investment would be needed to achieve at least one phase 2 outcome by EID, given existing and new preclinical vaccine candidates being made available?</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Objective</td>
    <td align="left">Minimise number of phase 2b–3 ready vaccine candidates (95% CI)</td>
    <td align="left">Minimise US$ cost associated with developing at least one phase 2b/3 ready vaccine candidate per EID (95% CI)</td>
   </tr>
   <tr>
    <td align="left">Decision variables</td>
    <td align="left">Number of new vaccine candidates initiating investment at preclinical, or phase 1, or phase 2</td>
    <td align="left">Number of ideal vaccine candidates initiating investment by R&amp;D phase; (number of existing vaccine candidates by R&amp;D phase + number of new preclinical vaccine candidates)</td>
   </tr>
   <tr>
    <td align="left">Input parameters</td>
    <td align="left">Number of vaccine candidates available in the pipeline from preclinical through phase 2 (by EID); PoS by R&amp;D phase (low 
     <italic>vs</italic> high PoS scenario)
     <xref rid="tbl2fn2" ref-type="table-fn">†</xref>
    </td>
    <td align="left">Number of vaccine candidates available in the pipeline from preclinical through phase 2 (by disease); Number of vaccine candidates newly made available in the pipeline at preclinical phase (by disease); Cost by R&amp;D phase (low 
     <italic>vs</italic> high cost distribution scenarios)
     <xref rid="tbl2fn2" ref-type="table-fn">†</xref>; PoS by R&amp;D phase (low 
     <italic>vs</italic> high PoS scenario)
     <xref rid="tbl2fn2" ref-type="table-fn">†</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Output parameters</td>
    <td align="left">Number of phase 2b/3 ready candidates (by disease; 95% CI)</td>
    <td align="left">Number of phase 2b–3 ready candidates (total and by disease) (95% CI); US$ for achieving phase 2b–3 ready candidates (total and by disease; 95% CI)</td>
   </tr>
   <tr>
    <td align="left">Constraints</td>
    <td align="left">Decision variables=integers; Decision variables=non-negative; Number of phase 2b–3 ready candidates (by disease) ≥1 (99% CI)</td>
    <td align="left">Decision variables=integers; Decision variables=non-negative; Decision variables≤available   + new preclinical pipelines; Decision variables≥ideal minimum pipelines for at least one phase 2b–3 ready candidate expected (by disease); Number of phase 2b–3 ready candidates (by disease) ≥1 (95% CI)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>PoS=probability of success. R&amp;D=research and development.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl2fn1">
   <label>*</label>
   <p id="cenpara10">Excluding Ebola owing to two phase 2 outcomes already having been achieved for this disease.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl2fn2">
   <label>†</label>
   <p id="cenpara20">Cost and PoS distributions by R&amp;D phase used in this model are provided in the 
    <xref rid="sec1" ref-type="sec">appendix</xref>.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
